Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors

Summary Background Proton pump inhibitors (PPIs) have been shown to be carcinogenic in rodent studies. Aim As part of a long‐term post‐marketing surveillance study requested by the US Food and Drug Administration, to compare incidence rates of gastric and other cancers after sustained exposures to p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2016-01, Vol.43 (1), p.73-82
Hauptverfasser: Schneider, J. L., Kolitsopoulos, F., Corley, D. A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 82
container_issue 1
container_start_page 73
container_title Alimentary pharmacology & therapeutics
container_volume 43
creator Schneider, J. L.
Kolitsopoulos, F.
Corley, D. A.
description Summary Background Proton pump inhibitors (PPIs) have been shown to be carcinogenic in rodent studies. Aim As part of a long‐term post‐marketing surveillance study requested by the US Food and Drug Administration, to compare incidence rates of gastric and other cancers after sustained exposures to pantoprazole, a long‐acting PPI, compared with other shorter acting PPIs. Methods We conducted a cohort study within the membership of the Kaiser Permanente Northern California healthcare system and compared rates of gastric and other cancers among pantoprazole users and users of other PPI medications. The Cox proportional hazards model was used to adjust for potential confounders such as sex, age, receipt of treatment for Helicobacter pylori, cumulative PPI dose, total years PPI treatment and year of index date. The study was developed in consultation with, and approved by, the FDA. Results A total of 61 684 persons with at least a 240‐day supply of medication (34 178 pantoprazole and 27 686 other PPIs) were followed up for a total of 547 020 person‐years (274 700 vs. 272 321 person‐years, respectively). The primary analyses demonstrated comparable risks between the pantoprazole and other PPI groups for gastric cancer [hazard ratio (HR) = 0.68, 95% CI 0.24–1.93); colorectal, liver, pancreatic, or small bowel cancers (HR = 0.95, 95% CI 0.65–1.40) or any cancer (HR = 1.06, 95% CI 0.93–1.21). Conclusions We found no evidence that pantoprazole, a longer acting PPI, compared with shorter‐acting agents, conferred an excess risk of gastric cancer, other gastrointestinal cancers or all cancers for pantoprazole compared with other shorter‐acting PPIs.
doi_str_mv 10.1111/apt.13450
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_apt_13450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>APT13450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4300-15a0a5cd5357acb37fee8af33c95efeb9b43339caa7fc4521d53c58d2940bd6c3</originalsourceid><addsrcrecordid>eNp1kE1OwzAQRi0EoqWw4ALIWyRS7DhOGnZVxZ9UCYTKOpo4DjUktmW7qsopODIpaREbZjOamTff4iF0TsmYdnUNNowpSzg5QEPKUh7FhKWHaEjiNI_iCWUDdOL9OyEkzUh8jAZxyhOaJmyIvl6U_8Cmxm_gg1MCC9BCuqt-NkoH6YPS0OwOHoOusAlL6fabGwxYmNaCU97obVZwEkIrdcBrFZbYgg7GOvg0jfzzbp0JHW9XrcVKL1WpgnH-FB3V0Hh5tusj9Hp3u5g9RPOn-8fZdB6JhBESUQ4EuKg44xmIkmW1lBOoGRM5l7Us8zJhjOUCIKtFwmPakYJPqjhPSFmlgo3QZZ8rnPHeybqwTrXgNgUlxdZq0Vktfqx27EXP2lXZyuqX3GvsgOseWKtGbv5PKqbPiz7yGzvahbk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Schneider, J. L. ; Kolitsopoulos, F. ; Corley, D. A.</creator><creatorcontrib>Schneider, J. L. ; Kolitsopoulos, F. ; Corley, D. A.</creatorcontrib><description>Summary Background Proton pump inhibitors (PPIs) have been shown to be carcinogenic in rodent studies. Aim As part of a long‐term post‐marketing surveillance study requested by the US Food and Drug Administration, to compare incidence rates of gastric and other cancers after sustained exposures to pantoprazole, a long‐acting PPI, compared with other shorter acting PPIs. Methods We conducted a cohort study within the membership of the Kaiser Permanente Northern California healthcare system and compared rates of gastric and other cancers among pantoprazole users and users of other PPI medications. The Cox proportional hazards model was used to adjust for potential confounders such as sex, age, receipt of treatment for Helicobacter pylori, cumulative PPI dose, total years PPI treatment and year of index date. The study was developed in consultation with, and approved by, the FDA. Results A total of 61 684 persons with at least a 240‐day supply of medication (34 178 pantoprazole and 27 686 other PPIs) were followed up for a total of 547 020 person‐years (274 700 vs. 272 321 person‐years, respectively). The primary analyses demonstrated comparable risks between the pantoprazole and other PPI groups for gastric cancer [hazard ratio (HR) = 0.68, 95% CI 0.24–1.93); colorectal, liver, pancreatic, or small bowel cancers (HR = 0.95, 95% CI 0.65–1.40) or any cancer (HR = 1.06, 95% CI 0.93–1.21). Conclusions We found no evidence that pantoprazole, a longer acting PPI, compared with shorter‐acting agents, conferred an excess risk of gastric cancer, other gastrointestinal cancers or all cancers for pantoprazole compared with other shorter‐acting PPIs.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.13450</identifier><identifier>PMID: 26541643</identifier><language>eng</language><publisher>England</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles - administration &amp; dosage ; Adolescent ; Adult ; Aged ; California ; Cohort Studies ; Dose-Response Relationship, Drug ; Female ; Helicobacter pylori ; Humans ; Male ; Middle Aged ; Neoplasms - epidemiology ; Proportional Hazards Models ; Proton Pump Inhibitors - administration &amp; dosage ; Stomach Neoplasms - epidemiology ; Time Factors ; United States ; Young Adult</subject><ispartof>Alimentary pharmacology &amp; therapeutics, 2016-01, Vol.43 (1), p.73-82</ispartof><rights>2015 John Wiley &amp; Sons Ltd</rights><rights>2015 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4300-15a0a5cd5357acb37fee8af33c95efeb9b43339caa7fc4521d53c58d2940bd6c3</citedby><cites>FETCH-LOGICAL-c4300-15a0a5cd5357acb37fee8af33c95efeb9b43339caa7fc4521d53c58d2940bd6c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.13450$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.13450$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26541643$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schneider, J. L.</creatorcontrib><creatorcontrib>Kolitsopoulos, F.</creatorcontrib><creatorcontrib>Corley, D. A.</creatorcontrib><title>Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors</title><title>Alimentary pharmacology &amp; therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary Background Proton pump inhibitors (PPIs) have been shown to be carcinogenic in rodent studies. Aim As part of a long‐term post‐marketing surveillance study requested by the US Food and Drug Administration, to compare incidence rates of gastric and other cancers after sustained exposures to pantoprazole, a long‐acting PPI, compared with other shorter acting PPIs. Methods We conducted a cohort study within the membership of the Kaiser Permanente Northern California healthcare system and compared rates of gastric and other cancers among pantoprazole users and users of other PPI medications. The Cox proportional hazards model was used to adjust for potential confounders such as sex, age, receipt of treatment for Helicobacter pylori, cumulative PPI dose, total years PPI treatment and year of index date. The study was developed in consultation with, and approved by, the FDA. Results A total of 61 684 persons with at least a 240‐day supply of medication (34 178 pantoprazole and 27 686 other PPIs) were followed up for a total of 547 020 person‐years (274 700 vs. 272 321 person‐years, respectively). The primary analyses demonstrated comparable risks between the pantoprazole and other PPI groups for gastric cancer [hazard ratio (HR) = 0.68, 95% CI 0.24–1.93); colorectal, liver, pancreatic, or small bowel cancers (HR = 0.95, 95% CI 0.65–1.40) or any cancer (HR = 1.06, 95% CI 0.93–1.21). Conclusions We found no evidence that pantoprazole, a longer acting PPI, compared with shorter‐acting agents, conferred an excess risk of gastric cancer, other gastrointestinal cancers or all cancers for pantoprazole compared with other shorter‐acting PPIs.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles - administration &amp; dosage</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>California</subject><subject>Cohort Studies</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - epidemiology</subject><subject>Proportional Hazards Models</subject><subject>Proton Pump Inhibitors - administration &amp; dosage</subject><subject>Stomach Neoplasms - epidemiology</subject><subject>Time Factors</subject><subject>United States</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1OwzAQRi0EoqWw4ALIWyRS7DhOGnZVxZ9UCYTKOpo4DjUktmW7qsopODIpaREbZjOamTff4iF0TsmYdnUNNowpSzg5QEPKUh7FhKWHaEjiNI_iCWUDdOL9OyEkzUh8jAZxyhOaJmyIvl6U_8Cmxm_gg1MCC9BCuqt-NkoH6YPS0OwOHoOusAlL6fabGwxYmNaCU97obVZwEkIrdcBrFZbYgg7GOvg0jfzzbp0JHW9XrcVKL1WpgnH-FB3V0Hh5tusj9Hp3u5g9RPOn-8fZdB6JhBESUQ4EuKg44xmIkmW1lBOoGRM5l7Us8zJhjOUCIKtFwmPakYJPqjhPSFmlgo3QZZ8rnPHeybqwTrXgNgUlxdZq0Vktfqx27EXP2lXZyuqX3GvsgOseWKtGbv5PKqbPiz7yGzvahbk</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Schneider, J. L.</creator><creator>Kolitsopoulos, F.</creator><creator>Corley, D. A.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201601</creationdate><title>Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors</title><author>Schneider, J. L. ; Kolitsopoulos, F. ; Corley, D. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4300-15a0a5cd5357acb37fee8af33c95efeb9b43339caa7fc4521d53c58d2940bd6c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles - administration &amp; dosage</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>California</topic><topic>Cohort Studies</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - epidemiology</topic><topic>Proportional Hazards Models</topic><topic>Proton Pump Inhibitors - administration &amp; dosage</topic><topic>Stomach Neoplasms - epidemiology</topic><topic>Time Factors</topic><topic>United States</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schneider, J. L.</creatorcontrib><creatorcontrib>Kolitsopoulos, F.</creatorcontrib><creatorcontrib>Corley, D. A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schneider, J. L.</au><au>Kolitsopoulos, F.</au><au>Corley, D. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors</atitle><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2016-01</date><risdate>2016</risdate><volume>43</volume><issue>1</issue><spage>73</spage><epage>82</epage><pages>73-82</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary Background Proton pump inhibitors (PPIs) have been shown to be carcinogenic in rodent studies. Aim As part of a long‐term post‐marketing surveillance study requested by the US Food and Drug Administration, to compare incidence rates of gastric and other cancers after sustained exposures to pantoprazole, a long‐acting PPI, compared with other shorter acting PPIs. Methods We conducted a cohort study within the membership of the Kaiser Permanente Northern California healthcare system and compared rates of gastric and other cancers among pantoprazole users and users of other PPI medications. The Cox proportional hazards model was used to adjust for potential confounders such as sex, age, receipt of treatment for Helicobacter pylori, cumulative PPI dose, total years PPI treatment and year of index date. The study was developed in consultation with, and approved by, the FDA. Results A total of 61 684 persons with at least a 240‐day supply of medication (34 178 pantoprazole and 27 686 other PPIs) were followed up for a total of 547 020 person‐years (274 700 vs. 272 321 person‐years, respectively). The primary analyses demonstrated comparable risks between the pantoprazole and other PPI groups for gastric cancer [hazard ratio (HR) = 0.68, 95% CI 0.24–1.93); colorectal, liver, pancreatic, or small bowel cancers (HR = 0.95, 95% CI 0.65–1.40) or any cancer (HR = 1.06, 95% CI 0.93–1.21). Conclusions We found no evidence that pantoprazole, a longer acting PPI, compared with shorter‐acting agents, conferred an excess risk of gastric cancer, other gastrointestinal cancers or all cancers for pantoprazole compared with other shorter‐acting PPIs.</abstract><cop>England</cop><pmid>26541643</pmid><doi>10.1111/apt.13450</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-2813
ispartof Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (1), p.73-82
issn 0269-2813
1365-2036
language eng
recordid cdi_crossref_primary_10_1111_apt_13450
source MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection)
subjects 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage
Adolescent
Adult
Aged
California
Cohort Studies
Dose-Response Relationship, Drug
Female
Helicobacter pylori
Humans
Male
Middle Aged
Neoplasms - epidemiology
Proportional Hazards Models
Proton Pump Inhibitors - administration & dosage
Stomach Neoplasms - epidemiology
Time Factors
United States
Young Adult
title Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A30%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20of%20gastric%20cancer,%20gastrointestinal%20cancers%20and%20other%20cancers:%20a%20comparison%20of%20treatment%20with%20pantoprazole%20and%20other%20proton%20pump%20inhibitors&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Schneider,%20J.%20L.&rft.date=2016-01&rft.volume=43&rft.issue=1&rft.spage=73&rft.epage=82&rft.pages=73-82&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.13450&rft_dat=%3Cwiley_cross%3EAPT13450%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26541643&rfr_iscdi=true